Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR associated (Cas) effector proteins enable the targeting of DNA double-strand breaks (DSBs) to defined loci based on a variable length RNA guide specific to each effector. The guide RNAs are generally similar in size and form, consisting of a ~20 nucleotide sequence complementary to the DNA target and an RNA secondary structure recognized by the effector. However, the effector proteins vary in Protospacer Adjacent Motif (PAM) requirements, nuclease activities, and DNA binding kinetics. Recently, ErCas12a, a new member of the Cas12a family, was identified in Eubacterium rectale. Here, we report the first characterization of ErCas12a activity in zebrafish and human cells. Using a fluorescent reporter system, we show that CRISPR/ErCas12a elicits strand annealing mediated DNA repair more efficiently than CRISPR/Cas9. Further, using our previously reported gene targeting method that utilizes short homology, GeneWeld, we demonstrate the use of CRISPR/ErCas12a to integrate reporter alleles into the genomes of both zebrafish and human cells. Together, this work provides methods for deploying an additional CRISPR/Cas system, thus increasing the flexibility researchers have in applying genome engineering technologies.
Introduction
CRISPR systems have been widely adopted in zebrafish research due to their efficacy and ease of reprogramming DNA binding activity, which is mediated by a single chimeric short guide RNA (sgRNA) molecule 1 2 3 . The CRISPR toolbox continues to expand with the identification of systems that display varying PAM requirements and produce a different DSB architecture 4 . While Cas9 proteins often hydrolyze DNA leaving a blunt-ended cut three base pairs (bps) upstream from the 5' end of the PAM sequence, Cas12a proteins from Acidaminococcus and Lachnospiraceae spp. hydrolyze DNA in a staggered fashion, cutting on the 3' side of the PAM and leaving 5' single-stranded overhands of 4 nucleotides 5 . The architecture of the DSB and end resection products are critical determinants of DNA repair pathway activation. 6 . For example, inducing DNA overhangs with staggered CRISPR/Cas9 nickases targeted to opposite strands can stimulate precision genome engineering using oligonucleotides 7 . Thus, there is demand for CRISPR variants that generate different DSB architectures and elicit more predictable repair outcomes for precision genome engineering.
CRISPR/Cas12a activity has been reported in zebrafish by injection of sgRNA/Cas12a protein ribonucleoprotein (RNP) complexes 8, 9 . In these studies it was shown that Cas12a -mediated DNA cleavage could be further enhanced by a 34ºC heat shock or by co-targeting of nuclease dead Cas9 (dCas9) to the Cas12a target site, indicating that DNA melting is a potential rate limiting step for Cas12a. Cas12a resulted in increased efficiency of oligonucleotide incorporation as compared to Cas9 into genomic cut sites by homology-directed repair, suggesting the two enzymes may employ distinct mechanisms and result in different genomic DNA end resection products 8 . A CRISPR/Cas12a system was identified in Eubacterium rectale, and found to be ancestrally related to the type V class II family of CRISPR proteins sharing the greatest similarity with Cas12a from Acidaminococcus sp. (AsCas12a) (Figure 1a ). Eubacterium rectale Cas12a (ErCas12a) is a 1262 amino acid protein that recognizes a 5'-YTTN PAM and uses a 42 or 56 base guide RNA to recognize and catalyze site-specific DNA cleavage 10 . CRISPR/ErCas12a is active in human cells 10 , but its application for gene targeting in vivo and in vitro has yet to be described.
Microhomology mediated end joining (MMEJ) is a DNA repair pathway that uses short regions of homology between resected DNA ends to drive repair, leading to predictable outcomes after nuclease targeting 11 12 13 . MMEJ-based gene editing and targeted integration Here, we report the successful application of ErCas12a for gene targeting in zebrafish, widely used to model development and disease, and in human cells. Consistent with its similarity to other Cas12a proteins, high ErCas12a activity requires a 34ºC heat shock treatment in zebrafish. However, injection of mRNA encoding for ErCas12a is sufficient to induce DSB activity, and pre-crRNA can serve as an effective RNA guide for ErCas12a, in contrast to reports using previously described Cas12a and related systems 8, 20 . We developed a Universal pre-crRNA (U-pre-crRNA) for ErCas12a which can be used in both zebrafish and human cells for donor DNA cleavage and show that CRISPR/ErCas12a potently induces strand annealing mediated repair (SAMR) in a genomic reporter locus at efficiencies greater than CRISPR/Cas9.
Additionally, CRISPR/ErCas12a promotes GeneWeld activity at rates similar to CRISPR/Cas9.
Finally, we apply GeneWeld with ErCas12a in human cells, and demonstrate ErCas12a mediated targeted integration activity at several human loci, including the safe harbor locus
AAVS1.

Results
ErCas12a induces indels in zebrafish embryos
We used informatic analyses to categorize a new potential gene editor (GenBank . To test ErCas12a gene editing activity in vivo, ErCas12a mRNA was co-injected with a pre-crRNA into single cell zebrafish embryos followed immediately by heat shock at 34 o C for 4 hours (Figure 1b) . Three pre-crRNAs and one crRNA were designed to target exon 1 of the zebrafish noto gene (Figure 1c ). Co-injection of ErCas12a mRNA with noto-pre-crRNA1 and incubation at 28ºC did not result in gene editing activity, similar to previous reports using Cas12a (Moreno-Mateos et al., 2017 8 and data not shown). However, injection of ErCas12a mRNA with noto-pre-crRNA1 or noto-pre-crRNA3 followed by a 4-hour 34ºC heat shock resulted in phenotypes characteristic of biallelic loss of noto, including loss of the notochord and a shortened tail 21 , at efficiencies ranging from 7-61% (Supplemental Figure 2a) . PCR across these individual target sites and subsequent heteroduplex mobility shift assays revealed the presence of indels characteristic of repair by NHEJ activity (Supplemental Figure 2b) . noto-precrRNA2 and noto-crRNA1 did not elicit a phenotype, and heteroduplex mobility shift assays across those targets indicate they are inactive sgRNAs (data not shown). Efficiencies of biallelic noto inactivation at the same target varied considerably from injection to injection (Supplemental .
To confirm that our results were not specific to a single locus, we shock, and that pre-crRNA can serve as an active RNA guide for directing ErCas12a activity to genomic target sites.
ErCas12a elicits strand annealing mediated DNA repair more efficiently than SpCas9 in a genomic reporter system in zebrafish
We next employed a stably integrated red fluorescent protein (RFP) reporter system to visually compare the efficiencies with which CRISPR/Cas9 and CRISPR/ErCas12a differentially elicit DNA repair using strand-annealing mediated repair (SAMR). We used GeneWeld to create a transgenic line of zebrafish that contain a single copy of an SAMR reporter, noto:RFP-DR48 We then tested whether CRISPR/ErCas12a promotes SAMR in the noto:RFP-DR48 assay. We designed a universal pre-crRNA (U-pre-crRNA), with no predicted off target sites in zebrafish or human cells, to direct ErCas12a activity to noto:RFP-DR48. Injection of ErCas12a mRNA and U-pre-crRNA resulted in RFP expression in the notochord (Figure 2b ).
Based on the percentage of injected animals with RFP+ notochords, ErCas12a elicited SAMR at a higher frequency than SpCas9 (Figure 2b ). Injected embryos were highly mosaic and qualitatively sorted into 3 classes of notochord RFP expression pattern: broad, intermediate, and narrow (Figure 2e-i) . While ~70% of ErCas12a-injected animals showed RFP+ cells in the notochord as opposed to ~40% in SpCas9-injected embryos, ErCas12a repair events are equally mosaic (Figure 2f ). These results indicate that noto:RFP-DR48 is a viable assay for screening the propensity of designer nucleases to elicit SAMR and that the enzymatic activity of ErCas12a enhances activation of SAMR over Cas9 in vivo.
Using ErCas12a for precise integrations in zebrafish
We leveraged the activity of the U-pre-crRNA to determine whether CRISPR/ErCas12a
can catalyze targeted integration of fluorescent reporters using GeneWeld
19
. First, we injected We next designed a GeneWeld donor with both 5' and 3' homology domains flanking the GFP cassette to promote precise repair at both sides of the integration site (Figure 3a) 19 .
Targeting noto using pre-crRNA3 with GeneWeld resulted in an average of 31% of embryos with GFP+ notochords (Figure 3b , 3b', 3c; Supplemental Table 4 ). Most notochords were highly mosaic and displayed GFP expression indicative of lost cell fate, as in noto target 1 targeting (Supplemental Figure 4b) , although some events were recovered in which >90% of the notochord expressed GFP (Figure 3b ). Predicted 5' and 3' junction fragments were recovered by PCR in GFP+ embryos (Figure 3d , 3e), and junction fragment sequencing from a single embryo demonstrated precise integration at both ends of the cassette (Figure 3f ). These data indicate that ErCas12a can be an effective nuclease for catalyzing integration in zebrafish using
GeneWeld, but that optimization is needed to enhance somatic integration efficiency to levels comparable to those obtained using Cas9.
ErCas12a induces double-strand breaks in human cells
We developed an all-in-one vector for expression of the dual nuclear localization signal ErCas12a and a pre-crRNA in vitro (Figure 4a ). We targeted two therapeutically relevant "safe harbor" loci, AAVS1 and CCR5 24 (Figure 4b, d ). We additionally targeted the TRAC locus due to its reported significance in generating Chimeric Antigen Receptor T cells (Figure 4e ) 25 . vitro cleavage activity of ErCas12a with our expression system was assessed using a T7 endonuclease (T7EI) assay to determine whether a DSB and subsequent indels were induced at the AAVS1 locus after transfection into HEK293 cells. The expected banding pattern was apparent in DNA amplified from pErCas12a-AAVS1-pre-crRNA1 transfected cells but not control cell DNA, indicating that ErCas12a was active at the AAVS1 target site (Figure 4c ). No indel activity was detected at the AAVS1 pre-crRNA2 site by T7E1 assay (data not shown). These data suggest that the all-in-one expression system is functional in vitro.
To gain a quantitative understanding of the cleavage activity of ErCas12a at the AAVS1, CCR5, TRAC target sites, PCR amplicons were submitted for Sanger sequencing and analyzed using ICE software, which infers CRISPR activity from sequencing trace reads Table 6 ).
Similarly, we tested 4 pre-crRNAs targeting TRAC and found the most efficient resulted in 60% of sequenced amplicons contained indels (Figure 4f , Supplementary Table 6 ). Because ICE is based on Sanger sequencing data, which considers fewer reads than NGS, it is likely to underestimate the true percentage of indels. We therefore measured indel activity at the AAVS1-pre-crRNA1 target site using Illumina sequencing, which showed that ~74% of recovered alleles were edited (Figure 4g ). Taken together, these data demonstrate that ErCas12a is active in human cells at clinically relevant genomic loci. 
Discussion
In this report, we establish that CRISPR/ErCas12a is an active nuclease in both zebrafish and human cells and can serve as an efficient alternative to CRISPR/Cas9 for generating HMEJ-mediated gene targeting events in vivo. Targeting in zebrafish embryos, we created frame shift indel alleles in the noto and cx43.4 at up to ~90% and ~24%, respectively.
ErCas12a activity is temperature-dependent in zebrafish and requires a 34ºC heat shock for activity. In a genomic reporter assay, ErCas12a elicits SAMR in a reporter assay at levels nearly 2-fold greater than Cas9 in both zebrafish and human cells. ErCas12a is also a viable nuclease . Although ErCas12a is an effective catalyst for GeneWeld integrations, mosaicism of expression is qualitatively higher than when using Cas9 as the GeneWeld . Though ErCas12a shares only 31% sequence homology with Cas12a orthologue AsCas12a (Supplemental Figure 1 ) and the RuvC domain is conserved among Cas12a orthologues and ErCas12a, it is possible that long range interactions at the catalytic pocket differ in ErCas12a due to the relatively low amino acid similarity.
Therefore, further studies are needed to elucidate if ErCas12a shares similar nonspecific nuclease activity.
Though Cas12a systems has been shown to be amendable to HDR-mediated integration, these transgene integration events have been shown to be highly dependent on using RNP complexes in concert with modified crRNAs to show appreciable activity 23 . Here, we demonstrate ErCas12a's utility in generating robust editing efficiency without chemically modified crRNAs, showing its utility in streamlined and accessible gene editing for most research applications. Further, we show ErCas12a mediates precise integration without engineering of the nuclease or the corresponding guide RNA with mRNA and plasmid DNA.
While we show that ErCas12a is compatible with GeneWeld. We also demonstrated that in the absence of the UgRNA liberating the donor there is still integration of the transgene at AAVS1. When GeneWeld is used with Cas9, the donor homology arms can include a portion of the genomic target but exclude the 3' PAM sequence and prevent nuclease targeting at the homology arms. However, because ErCas12a utilizes a 5' PAM and induces a distal DSB, it is likely that the homology arm is being targeted by ErCas12a and linearizing the donor at the 5'
end. In our design the homology arms contain up to 17bp of target region that may be sufficient for a Cas12a-like seed region for the crRNA and facilitate a DSB 40 41
. With further optimization of both the crRNA and donor constructs, ErCas12a can readily be adapted for precise integration in mammalian systems.
Conclusion
Alternative nuclease systems beyond canonical CRISPR/Cas9 are of interest in the precision therapeutics field as they expand the available toolbox for precision gene editing.
Here, we demonstrate effective genome editing in both zebrafish and human cells using the newly described CRISPR/ErCas12a system, which increases the number of accessible regions in the genome due to its AT-rich PAM sequence. In zebrafish, CRISPR/ErCas12a promotes efficient somatic mutation and HMEJ-mediated precise integration of donor cassettes. In human cells, CRISPR/ErCas12a efficiently targeted therapeutically relevant loci, including the safe harbor loci AAVS1 and CCR5, and facilitated transgene integration. Our data suggest that, with further optimization, ErCas12a may be an invaluable tool for gene editing in both basic research and future clinical gene therapy applications. 
Materials and methods
Zebrafish husbandry
Zebrafish were maintained in Aquatic Habitats (Pentair) housing on a 14 hour light/10 hour dark cycle. Wild-type WIK were obtained from the Zebrafish International Resource Center.
All experiments were carried out under approved protocols from Iowa State University IACUC.
nErCas12an cDNA cloning gBlocks were ordered from IDT with zebrafish codon optimized ErCas12A cDNA sequences based on Inscripta public disclosure and the addition of dual NLS sequences at the 5' and 3' end of the cDNA (Supplemental Table 1 ). Three gBlock dsDNA templates were 
Injection protocol
Linear, purified pT3TS-nCas9n or pT3TS-nErCas12an was used as template for in vitro transcription of capped, polyadenylated mRNA with the Ambion T3TS mMessage mMachine Kit.
mRNA was purified using Qiagen miRNeasy Kit. The Cas9 universal sgRNAs were generated using cloning free sgRNA synthesis as described in Varshney et al., 2015 and purified using Qiagen miRNeasy Kit. All ERCAS12A pre-crRNA and crRNA was ordered as custom RNA oligos from Synthego with sequences described in Figure 1a .
Heat shock protocol
Immediately after injection, embryos were placed in a 34ºC incubator for 4 hours. At 4 hours, embryos were sorted for fertilization and fertilized embryos were moved to 28ºC incubator as normal.
DNA isolation and PCR genotyping
Genomic DNA for PCR was extracted by digestion of single embryos in 50mM NaOH at 95ºC for 30 minutes and neutralized by addition of 1/10 th volume 1M Tris-HCl pH 8.0. GoTaq
Green was used as DNA polymerase master mix with the primers listed in Supplemental Table   2 . AmpliconEZ from GeneWiz was used for NGS sequencing (see below) using primers ErCas12anoto1fEZ and ErCas12anoto1rEZ for noto target 1, ErCas12anoto3fEZ and ErCas12anoto3rEZ for noto target 3, and cxm7gRNA2fEZ, cxm7gRNA2rEZ for cx43.4 listed in Supplemental Table 2 . GFP+ embryo 5' junction fragments for noto target 1 and target 3
were PCR-amplified with primer notojxnf and gfp5'r listed in Supplemental Table 2 . GFP+ embryo 3' junction fragments for noto target 3 were PCR-amplified with primer GFP3'F and notojxnr listed in Supplemental Table 2 . All junction fragment products were cloned into pCR4-TOPO vector and sequenced (Invitrogen).
Donor vector preparation
Donor vectors were prepared and purified as described previously (Wierson et al., 2018). Homology arms are built as follows: One arm begins 13 bp 3' of the PAM while the other arm begins immediately outside of the 3' end of the crRNA target site. See Figure 3 and Figure   4 for homology arm design, and Supplemental Table 3 for GeneWeld homology arm oligos used for Golden Gate cloning. Gene targeting oligos and donor vector sequences are listed in Supplemental Tables 2 and 3 .
Generating noto:RFP-DR48
Zebrafish RFP assay generation, injection, and line isolation pPRISM-V3 was PCR amplified with v3f and v3r to remove the ocean-POUT terminator and add SgrAI and SpeI cloning sites (Supplemental Table 2 ). Bactin 3' UTR was PCR amplified using added to pPRISM-V3-bactin RFP-DR48 using Golden Gate cloning as described in Wierson et al., 2018. The RFP cassette was liberated from the donor using the same noto sgRNA used to cut the genome. Gamma-crystalin:eGFP positive embryos were sorted and raised to adulthood, outcrossed to generate the F1 generation, and outcrossed again to generate lines of F2s.
Southern blot analysis
Genomic Southern blot and copy number analysis was performed as described previously 42 . PCR primers used for genomic and donor specific probes are listed in Supplemental Table 2 .
Cell culture
HEK293 cells were obtained from ATCC (CRL-3216). Cells were maintained in
Dulbecco's Modified Eagle Medium (Gibco #11995-040) supplemented with 10% fetal bovine serum (Gibco #26140079) and 1% Penicillin Streptomycin (Gibco #15140-122). Media was changed every 2-3 days and replated at final dilution of 1:10 maintained at about 750,000 cells/ml.
DNA isolation and Sequence analysis
DNA from whole cell populations was purified using Qiagen DNeasy Blood & Tissue Kit (Qiagen 69504). PCR amplification was performed with MyTaq DNA Polymerase (Bioline BIO-21108) and purified with Qiagen QIAquick PCR Purification kit (Qiagen 28104). Samples used for ICE analysis were submitted to GeneWiz Sanger Sequencing service.
Cloning in vitro ErCas12a construct targeting AAVS1 (pErCas12aErCas12a-AAVS1)
Due to redundant restriction sites in the guide scaffold and ErCas12a protein, the pX601-AAV-CMV::NLS-SaCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA plasmid (Addgene #61591) was digested with BsaI and NotI to first insert the ErCas12a secondary structure and sgRNA targeting AAVS1 with ErCas12a sgRNA AAVS1 top and ErCas12a sgRNA AAVS1 bottom (termed AAV: ErCas12a AAVS1 sgRNA) ( Table 3) . Following this ErCas12a as well as the Xenopus globin 5' UTR and both N and C termini SV40 NLS signals were amplified from "T3TS nErCas12an" using PCR primers ErCas12a AgeI forward and ErCas12a BamHI reverse (Supplemental Table 1 
pErCas12a-AAVS1-U
pErCas12a-AAVS1-U was generated by inserting ErCas12a pre-U-crRNA into AAV 601
by digesting AAV601 with BsaI+ NotI and inserting annealed oligos ErCas12a UgRNA+Scaffold
Top and ErCas12a UgRNA+Scaffold Bottom. The U6 promoter, the cr-RNA scaffold and the Upre-crRNA were PCR amplified from AAV 601 using ErCas12a U6+ugRNA Primer PfoI Fw and ErCas12a U6+ugRNA Primer PfoI Rev. This PCR amplicon as well as pErCas12a-AAVS1 were digested with PfoI and ligated with T4 DNA ligase to generate pErCas12a-AAVS1-pre-crRNA1-U-pre-crRNA.
Generating knock-in cassette for AAVS1
The 24 and 48bp homology arm CMV/GFP/Zeocin resistance knock-in cassettes were generated by designing PCR primers complementary to the psiRNA-SV40 Early PolyA GFPzeo plasmid (Invivogen) flanked by the 48 base pairs of homology and the UgRNA sequence separated by a 3bp spacer. The left 48HA forward primer AAVSI T1 L48HA and the right 48HA reverse primer AAVS1 T1 R48HA 43 were used to amplify the CMV/GFP/Zeocin resistance cassette containing the homology arms and the UgRNA target sequence (Supplemental Table   2 , Supplemental UgRNA BsaI bottom to generate pErCas12a-U-pre-crRNA. Cas9 constructs targeting the UgRNA were generated by digesting lentiCRISPR v2 (Addgene #52961) with BsmBI and cloning in the annealed oligos Cas9 UgRNA BsmBI Top and Cas9 UgRNA BsmBI Bottom to generate pCas9-UgRNA. To control for promoter expression between ErCas12a and Cas9, the CMV promoter was added to pCas9-UgRNA by digesting ErCas12a EZ clone with XbaI and AgeI to remove the CMV promoter and pCas9-UgRNA with NheI and AgeI to replace the native EF1 alpha promoter.
HEK 293T cells were transfected with 5ug pMiniCAAGs:RFP-DR48 and 5ug of either pErCas12a-U-pre-crRNA or pCas9-UgRNA with the Etta H1 electroporator as described above.
Cells were assessed for RFP expression 48 hours later by flow cytometry with 584nm emission and 607nm detection. 
Data analysis
The raw Illumina reads were checked for adapters and quality via FastQC. The raw Illumina sequence reads were trimmed of their adapters and nucleotides with poor quality using Trimmomatic v. 0.36. Paired sequence reads were then merged to form a single sequence if the forward and reverse reads were able to overlap. The merged reads were aligned to the reference sequence and variant detection was performed using GENEWIZ proprietary Amplicon-EZ program.
Phylogeny and homology analysis
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